TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7806134
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (0.625 mg daily for 21 days) administered at 8 a.m.
Study: 6778331
Drug: Pulverized prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulverized prednisone tablets (5 mg)
Study: 6778331
Drug: Concomitant sulfisoxazole
Normalized name: Sulfisoxazole
DrugBank: Sulfisoxazole (DB00263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant sulfisoxazole suspension of 50 mg/kg/day twice daily
Study: 30991720
Drug: Sofrito (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofrito (240 g/70 kg)
Study: 20483003
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive craniopuncture combined with urokinase infusion therapy
Study: 16154019
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DES) - Cypher (n=264) and Taxus (n=281)
Study: 16154019
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DES) compared to Bare-metal stents (BMS)
Study: 7555458
Drug: Antacids, Cimetidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids, Cimetidine, Ranitidine
Study: 2190013
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B at a daily dose of 2,400 mg
Study: 2190013
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B at a daily dose of 1,200 mg
Study: 2190013
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B at a daily dose of 2,400 to 7,200 mg
Study: 2190013
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B at a daily dose of 4,800 mg
Study: 7317219
Drug: Systemic benzylpenicillin
Normalized name: benzylpenicillin
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic benzylpenicillin and flucloxacillin administered just before operation and one and six hours afterwards.
Study: 31835186
Drug: Alcohol (Males:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (Males: 0.68 g/kg; Females: 0.60 g/kg)
Study: 29180855
Drug: 0.025% capsaicin
Normalized name: CAPSAICIN 2.5 mg in 10 g TOPICAL PATCH [0.025% Capsaicin Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% capsaicin ointment
Study: 25785658
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (0.5‐1.5 IU/h) as a continuous subcutaneous insulin infusion (CSII) during transient hyperglycemia for 2 h (visit TH)
Study: 25785658
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (0.5‐1.5 IU/h) as a continuous subcutaneous insulin infusion (CSII) during continuous hyperglycemia for 12 h (visit CH)
Study: 25785658
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (0.5‐1.5 IU/h) as a continuous subcutaneous insulin infusion (CSII) during both visits
Study: 20491143
Drug: Conservative (restrictive)
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative (restrictive) infusion strategy
Study: 20491143
Drug: Liberal (traditional)
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal (traditional) infusion strategy
Study: 14662708
Drug: ADMA infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ADMA infusion at a dose of 0.25 mg ADMA x kg(‐1) x min(‐1)
Study: 14662708
Drug: N(G)-nitro-L-arginine methyl
Normalized name: methyl L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-nitro-L-arginine methyl ester infusion at a dose of 3 microg x kg(‐1) x min(‐1)
Study: 11703963
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with low-fat foods enriched with 1.25 to 5.0 g/day of nonesterified plant sterols and mineral nutrients (calcium, magnesium, potassium)
Study: 23092785
Drug: Rifaximin plus
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin plus fibre supplementation (400 mg b.d. for one week per month + 3.5 g high-fibre supplementation b.d.)
Study: 23092785
Drug: Fibre supplementation
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre supplementation alone (3.5 g high-fibre supplementation b.d.)
Study: 20525840
Drug: Combination glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination glucosamine and chondroitin sulphate
Study: 20525840
Drug: Chondroitin sulphate
Normalized name: Chondroitin sulphate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulphate 400 mg three times daily
Study: 10519500
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (250 microg/kg bolus followed by 13 microg x kg(‐1) x h(‐1) infusion)
Study: 10519500
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline (equivalent volume to lidocaine)
Study: 7492104
Drug: A77003 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A77003 at 0.035 mg/kg/h
Study: 7492104
Drug: A77003 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A77003 at 0.07 mg/kg/h
Study: 7492104
Drug: A77003 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A77003 at 0.14 mg/kg/h
Study: 7492104
Drug: A77003 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A77003 at 0.28 mg/kg/h
Study: 6182516
Drug: Oral combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral combined preparation (antihistamine + decongestant)
Study: 31407802
Drug: 0.5% G.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% G. speciosum ethanolic extract (GSE) serum applied for 56 days
Study: 25085517
Drug: CMT Neuropathy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMT Neuropathy Score (CMTNS) components including Ulnar compound motor action potential (CMAP), leg motor symptoms, arm motor symptoms, leg strength, and sensory symptoms
Study: 6742743
Drug: Midazolam alone
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam alone or in combination with pentazocine
Study: 31204771
Drug: ∼3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: ∼3 g/d DHA
Study: 31204771
Drug: ∼3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: ∼3 g/d EPA
Study: 27055965
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg/d)
Study: 27055965
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sesame oil blend and nifedipine (20 mg/d)
Study: 25194085
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for 15 days
Study: 25194085
Drug: Phytotherapeutic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytotherapeutic agents for 30 days plus 15 days antibiotic treatment
Study: 25194085
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Antibiotic treatment only for 15 days)
Study: 18043478
Drug: darunavir/ritonavir (400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir (400/100 mg) twice a day
Study: 18043478
Drug: saquinavir/ritonavir (1000/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: saquinavir/ritonavir (1000/100 mg) twice a day
Study: 18043478
Drug: darunavir/saquinavir/ritonavir (400/1000/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/saquinavir/ritonavir (400/1000/100 mg) twice a day
Study: 16107961
Drug: Undiluted Lancy-Vaxina
Normalized name: Fancy Falsegoldenaster Flower
DrugBank: Heterotheca inuloides flower (DB14331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undiluted Lancy-Vaxina vaccine (n=56)
Study: 16107961
Drug: Diluted Lancy-Vaxina
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted Lancy-Vaxina vaccine (n=56)
Study: 2305610
Drug: Glucose-free 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-free 2% lidocaine (80 mg)
Study: 2305610
Drug: Hyperbaric 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric 5% lidocaine (80 mg)
Study: 7386343
Drug: 167 mg
Normalized name: silymarin 167 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 167 mg of citrated caffeine
Study: 7386343
Drug: 324 mg
Normalized name: aspirin 324 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 324 mg of citrated caffeine
Study: 7386343
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of citrated caffeine
Study: 7386343
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg of caffeine)
Study: 31551249
Drug: HDV-insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HDV-insulin lispro (HDV-L)
Study: 19393928
Drug: Intra-articular shoulder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular shoulder injections using steroid with distension
Study: 16675705
Drug: Serogroup C
Normalized name: Neisseria meningitidis serogroup C Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serogroup C glycoconjugate vaccine
Study: 12934956
Drug: Real millimeter
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real millimeter wave therapy (MWT) sessions, n=4
Study: 10928302
Drug: Long-acting calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting calcium channel blockers
Study: 8623869
Drug: Antibiotics effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics effective against group B streptococci
Study: 1549403
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b Neisseria meningitidis outer membrane protein conjugate vaccine (PedvaxHIB)
Study: 4001836
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of porcine GIP at a dose of 1.0 microgram . kg‐1 . h‐1
Study: 29979421
Drug: Preoperative injection
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative injection of carbon nanoparticles (CNs)
Study: 29979421
Drug: Intraoperative injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative injection of carbon nanoparticles (CNs)
Study: 26890267
Drug: Intravenous preemptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous preemptive analgesia (IV-PCA) with fentanyl started before skin incision
Study: 24528331
Drug: warfarin transitioned
Approvals — FDA: no, EMA: no, PMDA: no
Description: warfarin transitioned to rivaroxaban 20 mg once daily (group A)
Study: 24528331
Drug: warfarin followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: warfarin followed by placebo once daily (group B)
Study: 24528331
Drug: rivaroxaban alone
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rivaroxaban alone 20 mg once daily (group C)
Study: 22222996
Drug: LipiFlow treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LipiFlow treatment (12 minutes)
Study: 22222996
Drug: iHeat Warm
Approvals — FDA: no, EMA: no, PMDA: no
Description: iHeat Warm Compress (5 minutes daily for 2 weeks)
Study: 22222996
Drug: LipiFlow treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LipiFlow treatment (12 minutes) in crossover group
Study: 12198044
Drug: Sufentanil target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil target concentration (STC) 0.1 ng/mL
Study: 12198044
Drug: Sufentanil target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil target concentration (STC) 0.2 ng/mL
Study: 12198044
Drug: Sufentanil target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil target concentration (STC) 0.3 ng/mL
Study: 12198044
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target concentration 5.0 microg/mL
Study: 12198044
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target concentration 4.0 microg/mL
Study: 12198044
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target concentration 2.5 microg/mL
Study: 11575576
Drug: Low group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low group (160 g of tomato juice plus 320 g of control drink)
Study: 11575576
Drug: High group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High group (480 g of tomato juice)
Study: 11575576
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (480 g of control drink)
Study: 8141442
Drug: Fentanyl/midazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl/midazolam (1 mg/25 mg; dosage 0.1 ml/kg/h)
Study: 8141442
Drug: Ketamine/midazolam (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine/midazolam (250 mg/25 mg; dosage 0.1 ml/kg/h)
Study: 2900980
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (n = 53) - second-look laparotomy followed by cyclical oral chlorambucil
Study: 2900980
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (n = 57) - oral chlorambucil without second-look operation
Study: 18465343
Drug: Oral pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pamidronate (150 mg twice daily for 4 years)
Study: 16540947
Drug: 4INJ group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4INJ group (n = 42) receiving four injections of methylprednisolone sodium succinate
Study: 16540947
Drug: 1INJ group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1INJ group (n = 42) receiving one injection of methylprednisolone followed by three injections of normal saline
Study: 16540947
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 43) receiving four injections of normal saline
Study: 10630947
Drug: Intraosseous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous injection of 1.8 mL of 3% mepivacaine
Study: 10630947
Drug: Mock intraosseous
Normalized name: mockernut extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mock intraosseous injection
Study: 1391258
Drug: Chlorothiazide (diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorothiazide (diuretic therapy)
Study: 16762982
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pioglitazone once daily for 4 weeks
Study: 16762982
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of TNF-alpha (10 ng/100 mL forearm volume/min for 2 h)
Study: 2892254
Drug: Nizatidine 30
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 30 mg
Study: 2892254
Drug: Nizatidine 100
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine 100 mg
Study: 13678868
Drug: Candesartan (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (titrated to 32 mg once daily)
Study: 10543583
Drug: Megadose Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megadose Vitamin C (1000 mg hourly for the first 6 hours, then 3 times daily thereafter)
Study: 10543583
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pain relievers and decongestants)
Study: 2070311
Drug: Split-virion vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-virion vaccine (SVV)
Study: 2070311
Drug: Whole-virion vaccine
Normalized name: Whole-Virion Inactivated SARS-CoV-2 Vaccine
DrugBank: BBV152 (DB15847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virion vaccine (WVV)
Study: 31524141
Drug: US-guided injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided injection (n=23)
Study: 31524141
Drug: Blind injection
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind injection (n=24)
Study: 28853992
Drug: Control cookies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cookies (CC)
Study: 26376447
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg, single dose)
Study: 23711703
Drug: Artemisinin combination
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin combination therapy (ACT) AS+SP
Study: 23711703
Drug: Artemisinin combination
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin combination therapy (ACT) AM+LF
Study: 12872150
Drug: IFN-α (IFN)
Normalized name: IFNγ
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-α (IFN) treatment
Study: 12872150
Drug: No IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: No IFN treatment (Control)
Study: 11091498
Drug: G-CSF (arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (arm A)
Study: 11091498
Drug: GM-CSF/G-CSF (arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF/G-CSF (arm C)
Study: 9350159
Drug: Intramuscular dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular dexamethasone (IMD)
Study: 9350159
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (OP)
Study: 31865628
Drug: Cannabis (300-μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis (300-μg/kg delta-9-tetrahydrocannabinol)
Study: 30220290
Drug: Multisymptom tablet
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisymptom tablet (containing paracetamol, pseudoephedrine hydrochloride, dextromethorphan hydrobromide, and chlorpheniramine maleate)
Study: 30220290
Drug: Multisymptom tablet
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisymptom tablet
Study: 27941973
Drug: Intravenous furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous furosemide (125-250mg/bid) plus hypertonic saline solution (HSS)
Study: 24888857
Drug: MBP+oral antibiotics
Normalized name: MBP-091
DrugBank: MBP-091 (DB17741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBP+oral antibiotics
Study: 24888857
Drug: Overall evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall evidence-based preparation
Study: 22226313
Drug: Homeopathic medicines
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic medicines
Study: 20307657
Drug: Microdose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdose (100 microg) of (14)C-drug administered orally
Study: 20307657
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose (120mg) of fexofenadine administered orally
Study: 20307657
Drug: Microdose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdose (100 microg) of (14)C-drug administered intravenously
Study: 20307657
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose (120mg) of fexofenadine administered with intravenous tracer dose (100 microg) of (14)C-drug
Study: 15816442
Drug: Total mesorectal
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total mesorectal excision (TME) with adjuvant systemic chemotherapy and radiotherapy
Study: 15816442
Drug: Total mesorectal
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total mesorectal excision (TME) with adjuvant stop-flow perfusion along with systemic chemotherapy
Study: 7044387
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of pirenzepine
Study: 7044387
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of pirenzepine
Study: 25847941
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice (IC) chemotherapy (n = 41)
Study: 25847941
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice (IC) chemotherapy (n = 11 with gpNMB overexpression)
Study: 25847941
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice (IC) chemotherapy (n = 11 with TNBC)
Study: 25847941
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice (IC) chemotherapy (n = 6 with gpNMB-overexpressing TNBC)
Study: 24905305
Drug: Vitamin-E along
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin-E along with regular medicines
Study: 24905305
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (pregabalin with oral hypoglycemic agents)
Study: 22822075
Drug: Calcium acetate,
Normalized name: Calcium Acetate, 667 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium acetate, lanthanum carbonate, sevelamer carbonate (active therapy)